AstraZeneca

Enhertu, AstraZeneca, Breakthrough Therapy Designations, HER2-positive cancers, Daiichi Sankyo, antibody drug conjugate, Trastuzumab Deruxtecan

FDA grants breakthrough status to T-DXd for two HER2-positive cancers

Anika Sharma

Daiichi Sankyo and AstraZeneca have garnered FDA Breakthrough Therapy Designations (BTDs) for their Enhertu (T-DXd) therapy to treat two distinct ...

AstraZeneca, Farxiga, heart failure, Chronic kidney diseases, European Society of Cardiology

Unveiling the Intricate Symphony: AstraZeneca’s Farxiga at the Heart of Cardiorenal Insights

Anika Sharma

In the heart of Amsterdam, amidst the captivating backdrop of the European Society of Cardiology (ESC) scientific sessions, AstraZeneca wielded ...

AstraZeneca, Rare Disease Research Funding, IRA, Centers for Medicare and Medicaid Services, Inflation Reduction Act, Orphan Drug Act, Lynparza

Legal Skirmishes Erupt as AstraZeneca Delves into Battle Over Drug Pricing Reforms with IRA

Anika Sharma

As the clock ticks down to the eagerly awaited unveiling of the Centers for Medicare and Medicaid Services’ (CMS) list ...

Roche, Horizon Therapeutics, Takeda, AstraZeneca, Octapharma

Horizon Surpasses Roche in Rare Disease Reputation, While Pfizer’s Standing Declines

Anika Sharma

Horizon Therapeutics continues to collect accolades as it progresses toward its acquisition, with rare disease organizations now recognizing its excellence. ...

AstraZeneca, Breztri, FDA, FDA warning letter, AstraZeneca Misleading Ads

FDA Issues Warning Letter to AstraZeneca Regarding ‘Misleading’ Breztri Efficacy Claims

Anika Sharma

AstraZeneca’s promotional campaign for Breztri Aerosphere, a treatment for chronic obstructive pulmonary disease (COPD), has encountered significant regulatory turbulence, with ...

Covid 19, Vaccination, BioNTech, Pfizer, Moderna, AstraZeneca

Twitter and BioNTech under fire for evading COVID-19 vaccine questions

SG Tylor

The regulatory organization overseeing the German communications sector has accused BioNTech of attempting to evade a public discussion regarding vaccine ...

How Daiichi Sankyo Will Rule the Antibody-Drug Conjugates Market by 2029

Daiichi Sankyo to Dominate Antibody-Drug Conjugates Market by 2029

SG Tylor

Daiichi has successfully established ADCs (Antibody-Drug Conjugates) as a significant therapeutic approach, overcoming previous years of underwhelming results. Even though ...

AZ and BMS End Patent Disputes Over Checkpoint Inhibitors

Checkpoint inhibitor patent challenges are settled by AZ and BMS

SG Tylor

AstraZeneca has announced the resolution of three lawsuits filed against it by Bristol-Myers Squibb (BMS) and Ono Pharma, alleging patent ...

AstraZeneca pays $510M to end cancer drug patent war

Blockbuster Cancer Immunotherapy Showdown Ends: Bristol Myers Squibb and AstraZeneca Settle Patents Clash

SG Tylor

Bristol Myers Squibb (BMS) and AstraZeneca have quickly resolved patent infringement lawsuits related to their cancer immunotherapies. The companies reached ...

AstraZeneca Sees China Sales Growth, Refutes Spinoff Report

AstraZeneca Expects Higher China Sales, Denies Spinoff Report

SG Tylor

AstraZeneca’s CEO Pascal Soriot has denied a report that the company is considering spinning off its China business, which is ...

Enhertu Boosts Survival in HER2+ Solid Tumors

Enhertu increases survival in solid tumors with HER2+

SG Tylor

AstraZeneca and Daiichi Sankyo have received a boost in their efforts to gain approval for Enhertu as a therapy for ...

Sharon Barr Is Appointed Executive Vice President Of Biopharmaceuticals R&D By AstraZeneca

Sharon Barr is appointed executive vice president of biopharmaceuticals R&D by AstraZeneca

SG Tylor

Source – AstraZeneca AstraZeneca has made a significant leadership announcement, appointing Sharon Barr as the new Executive Vice President for ...

UK Probes Suicide Risk of Popular Diabetes Drugs

The UK is looking into GLP-1 medications made by Novo Nordisk, AstraZeneca, Lilly, and Sanofi for GLP-1 inhibitor suicide risk

SG Tylor

Following the European Union’s lead, the United Kingdom has initiated an investigation into the potential suicide risks associated with popular ...

Soliris: EU Approves Breakthrough gMG Treatment for Kids

A New Hope for Children and Teens with gMG: Soliris Gets EU Approval

SG Tylor

Source – AstraZeneca The European Union (EU) has granted approval for the expanded use of Soliris (eculizumab) to treat refractory ...

EU Approves Jardiance for CKD: Forxiga Faces Tough Rival

Jardiance Receives EU Approval for Treating Chronic Kidney Disease (CKD), Posing a Strong Challenge to Forxiga

SG Tylor

Source – Boehringer Ingelheim The European Union has granted approval for Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor, Jardiance (empagliflozin), ...

AstraZeneca and SK Chemicals Join Forces to Create Sidapvia, a Novel Diabetic Medication

Powerful Alliance: AstraZeneca Teams Up with SK Chemicals to Revolutionize Diabetes Treatment with Sidapvia Combo Drug

SG Tylor

Korea’s SK Chemicals has recently entered into an agreement with AstraZeneca to manufacture the diabetes drug Sidapvia for the remainder ...

Pieris Cuts Jobs and Programs After AZ Drops Out of Elarekibep Deal

Pieris Takes Drastic Measures Following AstraZeneca Partnership Loss for Elarekibep

SG Tylor

Source – Pieris Pharmaceuticals AstraZeneca has ended its collaboration with Pieris Pharmaceuticals on the respiratory drug candidate elarekibep, leading Pieris ...

FDA has approved Beyfortus as a treatment for RSV illness in newborns

FDA has approved Beyfortus as a treatment for RSV illness in newborns

SG Tylor

Source – Sanofi On July 17, 2023 Sanofi and AstraZeneca received approval from the US Food and Drug Administration (FDA) ...

Enhertu Receives Approval in China as Groundbreaking HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer Patients

Enhertu Receives Approval in China as Groundbreaking HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer Patients

SG Tylor

Source – AstraZeneca  Enhertu (trastuzumab deruxtecan), a targeted antibody drug conjugate developed by AstraZeneca and Daiichi Sankyo, has received approval ...

Datopotamab Deruxtecan Meets Dual Primary Endpoint in TROPION-Lung01 Phase III Trial for Advanced Non-Small Cell Lung Cancer - Pharmtales

DATOPOTAMAB DERUXTECAN MEETS DUAL PRIMARY ENDPOINT IN TROPION-LUNG01 PHASE III TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER

SG Tylor

On July 3, 2023, AstraZeneca presented encouraging top-line results from the TROPION-Lung01 Phase III trial that demonstrated the positive efficacy ...

Imfinzi + Imjudo Unprecedented 4-Year Survival in Advanced Liver Cancer | Pharmtales

Imfinzi + Imjudo: Unprecedented 4-Year Survival in Advanced Liver Cancer

SG Tylor

Source – AstraZeneca On 29 June 2023, new  findings from the HIMALAYA Phase III trial revealed that AstraZeneca’s Imfinzi (durvalumab) ...

AstraZeneca Invests $400M in Reforestation and Biodiversity _ Pharmtales - Latest Pharma News & Insights

AstraZeneca Invests $400M in Reforestation and Biodiversity

SG Tylor

Source – AstraZeneca  AstraZeneca has made a significant announcement of a $400 million investment in its global AZ Forest program, ...

Xigduo XR Receives Approval in China for the Treatment of Type II Diabetes in Adults

Xigduo XR Receives Approval in China for the Treatment of Type II Diabetes in Adults

SG Tylor

Source – AstraZeneca  On June 27, 2023, AstraZeneca’s Xigduo XR, a once-daily fixed-dose combination of dapagliflozin and metformin hydrochloride extended-release, ...

Addressing Low Diagnosis Rates for Kidney Disease: The Urgent Need for Better Screening, as Highlighted by AstraZeneca

Addressing Low Diagnosis Rates for Kidney Disease: The Urgent Need for Better Screening, as Highlighted by AstraZeneca

SG Tylor

How AstraZeneca’s Research Shows the Need for Improved Screening Methods to Tackle Low Diagnosis Rates for Kidney Disease AstraZeneca, the ...

Significant Surge in Biologic Medications for Lupus Treatment as Rheumatologists Shift Away from Traditional Off-Label Therapies

Significant Surge in Biologic Medications for Lupus Treatment as Rheumatologists Shift Away from Traditional Off-Label Therapies

SG Tylor

A recent analysis conducted by Spherix Global Insights reveals a notable increase in the utilization of new biologic drugs, namely ...

In the US, patients with advanced HR-positive breast cancer are given priority review for the combination of capivasertib and Faslodex

In the US, patients with advanced HR-positive breast cancer are given priority review for the combination of capivasertib and Faslodex

SG Tylor

Source- Astrazeneca The US Food and Drug Administration (FDA) has accepted and granted Priority Review to AstraZeneca’s New Drug Application ...

For the treatment of people with refractory generalized myasthenia gravis, Soliris has received approval in China

For the treatment of people with refractory generalized myasthenia gravis, Soliris has received approval in China

SG Tylor

Source- Astrazeneca For the treatment of adult patients with refractory generalized myasthenia gravis (gMG) and anti-acetylcholine receptor (AChR) antibody positivity, ...

FDA Advisory Committee Unanimously Recommends Nirsevimab for Preventing RSV Lower Respiratory Tract Disease in Infants

FDA Advisory Committee Unanimously Recommends Nirsevimab for Preventing RSV Lower Respiratory Tract Disease in Infants

SG Tylor

Source: AstraZeneca The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously, with a 21 to 0 decision, affirming the ...

Danicopan Shows Promise as an Add-On to Ultomiris or Soliris, Enhancing Hemoglobin Levels and Disease Control in PNH Patients

Danicopan Shows Promise as an Add-On to Ultomiris or Soliris, Enhancing Hemoglobin Levels and Disease Control in PNH Patients

SG Tylor

Source – AstraZeneca Promising outcomes emerged from the pivotal Phase III ALPHA trial, revealing that danicopan, an investigational oral Factor ...

AstraZeneca Enters $2 Billion Deal with Quell for Treg Cell Therapy

AstraZeneca Enters $2 Billion Deal with Quell for Treg Cell Therapy

SG Tylor

British start-up Quell Therapeutics has secured a collaboration with AstraZeneca focused on cell therapies for autoimmune diseases, with an upfront ...